Compare Twist Bioscience Corp (TWST) vs Veeva Systems (VEEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Veeva Systems — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Veeva Systems trades at $260.88 (market cap $42.88B). The key difference: Veeva Systems is far larger — about 5.1× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| TWST | VEEV | |
|---|---|---|
Market Cap | $8.42B | $42.88B |
Sector | Health | Technology |
52-Week High | $153.10 | $306.22 |
52-Week Low | $24.16 | $151.43 |
Enterprise Value | $8.35B | $35.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Veeva Systems
Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →
